Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Athenex Inc is a drug manufacturers-specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 652 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $0.49 |
|---|---|
| 52-week range | $0.41 - $4.53 |
| 50-day moving average | $0.51 |
| 200-day moving average | $1.36 |
| Wall St. target price | $2.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.78 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.487 from 2022-07-05
| 1 week (2022-06-30) | 19.07% |
|---|---|
| 1 month (2022-06-03) | -1.34% |
| 3 months (2022-04-07) | -41.40% |
| 6 months (2022-01-06) | -63.11% |
| 1 year (2021-07-07) | -87.92% |
|---|---|
| 2 years (2020-07-07) | -96.34% |
| 3 years (2019-07-05) | 19.6 |
| 5 years (2017-07-07) | 18.42 |
| Revenue TTM | $108.9 million |
|---|---|
| Gross profit TTM | $37.8 million |
| Return on assets TTM | -25.19% |
| Return on equity TTM | -244.69% |
| Profit margin | -176.47% |
| Book value | $0.34 |
| Market capitalisation | $45.8 million |
TTM: trailing 12 months
We're not expecting Athenex to pay a dividend over the next 12 months.
Over the last 12 months, Athenex's shares have ranged in value from as little as $0.405 up to $4.525. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.9657. This would suggest that Athenex's shares are less volatile than average (for this exchange).
Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.